Group 1 - The core viewpoint of the news highlights the performance of the domestic vaccine market, with significant increases in the stock prices of key companies such as Heng Rui Medicine and Yi Fan Medicine, indicating a positive market sentiment towards the vaccine sector [1] - As of July 26, 2025, Guangdong Province reported 2,940 new local cases of Chikungunya fever, with no severe cases or deaths, suggesting a growing public health concern that may drive demand for vaccines [1] - The vaccine enterprises primarily operate in the domestic market, with substantial potential for domestic substitution and technological iteration, indicating a robust growth opportunity in the sector [1] Group 2 - The National Vaccine and Biotechnology Index consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the Shanghai and Shenzhen stock exchanges [2] - As of June 30, 2025, the top ten weighted stocks in the National Vaccine and Biotechnology Index accounted for 64.83% of the index, with notable companies including Fosun Pharma and Changchun High-tech [2]